These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 30137641)

  • 21. Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis.
    Kearsley-Fleet L; Baildam E; Beresford MW; Douglas S; Foster HE; Southwood TR; Hyrich KL; Ciurtin C
    Rheumatology (Oxford); 2023 May; 62(5):1926-1935. PubMed ID: 36104094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tocilizumab for juvenile idiopathic arthritis: a single-center case series.
    Yazılıtaş F; Özdel S; Şimşek D; Aydoğ Ö; Çakıcı EK; Can GG; Güngör T; Bülbül M
    Sao Paulo Med J; 2019; 137(6):517-522. PubMed ID: 32159638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early Treatment and IL1RN Single-Nucleotide Polymorphisms Affect Response to Anakinra in Systemic Juvenile Idiopathic Arthritis.
    Pardeo M; Rossi MN; Pires Marafon D; Sacco E; Bracaglia C; Passarelli C; Caiello I; Marucci G; Insalaco A; Perrone C; Tulone A; Prencipe G; De Benedetti F
    Arthritis Rheumatol; 2021 Jun; 73(6):1053-1061. PubMed ID: 33615724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis on anti-interleukin-1 or -6 therapy.
    Ulu K; Aliyev E; Kılıç Könte E; Tanatar A; Türkmen Ş; Doğantan Ş; Kızıldağ Z; Kasap Demir B; Gezgin Yıldırım D; Otar Yener G; Öztürk K; Baba Ö; Açarı C; Kılbaş G; Taşkın SN; Haşlak F; Çağlayan Ş; Bağlan E; Dundar HA; Başaran Ö; Barut K; Karadağ ŞG; Coşkuner T; Sönmez HE; Yüksel S; Kalyoncu M; Bakkaloğlu SA; Ünsal E; Paç Kısaarslan A; Bilginer Y; Aktay Ayaz N; Kasapçopur Ö; Özen S; Sözeri B
    Rheumatology (Oxford); 2024 Sep; 63(SI2):SI167-SI172. PubMed ID: 38441301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis.
    Grönlund MM; Remes-Pakarinen T; Kröger L; Markula-Patjas K; Backström M; Putto-Laurila A; Aalto K; Vähäsalo P
    Rheumatology (Oxford); 2020 Apr; 59(4):732-741. PubMed ID: 31359057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
    Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
    Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom.
    Kearsley-Fleet L; Sampath S; McCann LJ; Baildam E; Beresford MW; Davies R; De Cock D; Foster HE; Southwood TR; Thomson W; Hyrich KL
    Rheumatology (Oxford); 2019 Feb; 58(2):331-335. PubMed ID: 30358861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients.
    Romano M; Pontikaki I; Gattinara M; Ardoino I; Donati C; Boracchi P; Meroni PL; Gerloni V
    Reumatismo; 2014 Mar; 65(6):278-85. PubMed ID: 24705031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy and safety of different drugs in patients with systemic juvenile idiopathic arthritis: A systematic review and network meta-analysis.
    Wang B; Zhang Y; Zhao Z; Ping J; Zhou L; Wang Y; Zhang Y
    Medicine (Baltimore); 2024 May; 103(18):e38002. PubMed ID: 38701278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis.
    DeWitt EM; Kimura Y; Beukelman T; Nigrovic PA; Onel K; Prahalad S; Schneider R; Stoll ML; Angeles-Han S; Milojevic D; Schikler KN; Vehe RK; Weiss JE; Weiss P; Ilowite NT; Wallace CA;
    Arthritis Care Res (Hoboken); 2012 Jul; 64(7):1001-10. PubMed ID: 22290637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
    Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
    Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis.
    Baris HE; Anderson E; Sozeri B; Dedeoglu F
    Clin Rheumatol; 2018 Dec; 37(12):3263-3273. PubMed ID: 30238379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biotechnological therapeutic in Juvenile Idiopathic Arthritis: Pathophysiological implications and targeted therapies.
    Pinto AM; Ascenção I; Rodrigues M; Brito I
    ARP Rheumatol; 2023; 2(4):299-306. PubMed ID: 38174749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis.
    Saccomanno B; Tibaldi J; Minoia F; Bagnasco F; Pistorio A; Guariento A; Caorsi R; Consolaro A; Gattorno M; Ravelli A
    J Rheumatol; 2019 Apr; 46(4):416-421. PubMed ID: 30647180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis.
    Brunner HI; Chen C; Bovis F; De Benedetti F; Espada G; Joos R; Akikusa J; Chaitow J; Boteanu AL; Kimura Y; Rietschel C; Siri D; Smolewska E; Schmeling H; Brown DE; Martini A; Lovell DJ; Huang B; Ruperto N;
    Arthritis Care Res (Hoboken); 2021 Sep; 73(9):1264-1274. PubMed ID: 32702212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biotherapy in juvenile idiopathic arthritis Moroccan patients: a single-center experience.
    Bouayed K; Hamraoui D; Mikou N; Sakhi A; Hilmi W
    Pan Afr Med J; 2022; 41():135. PubMed ID: 35519160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: A single-center experience.
    Barut K; Adrovic A; Sahin S; Tarcin G; Tahaoglu G; Koker O; Yildiz M; Kasapcopur O
    Int J Rheum Dis; 2019 Sep; 22(9):1661-1669. PubMed ID: 31273940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis - data from the German BIKER registry.
    Atemnkeng Ntam V; Klein A; Horneff G
    Expert Opin Drug Saf; 2021 Jan; 20(1):93-100. PubMed ID: 33148061
    [No Abstract]   [Full Text] [Related]  

  • 40. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.
    De Benedetti F; Brunner HI; Ruperto N; Kenwright A; Wright S; Calvo I; Cuttica R; Ravelli A; Schneider R; Woo P; Wouters C; Xavier R; Zemel L; Baildam E; Burgos-Vargas R; Dolezalova P; Garay SM; Merino R; Joos R; Grom A; Wulffraat N; Zuber Z; Zulian F; Lovell D; Martini A; ;
    N Engl J Med; 2012 Dec; 367(25):2385-95. PubMed ID: 23252525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.